Navigation Links
Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call
Date:4/10/2017

LAVAL, Quebec, April 10, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") today announced that it will conduct a live webcast of the Company's annual meeting of shareholders for the year-ended December 31, 2016. 

The meeting will be held on Tuesday, May 2, 2017 at 9:00 a.m. ET at the Company's offices located at 2150 Saint Elzear Blvd. West, Laval, Quebec, Canada, H7L 4A8.  Only shareholders of record at the close of business on the record date of March 7, 2017, will be entitled to vote at the meeting.

A live webcast and audio archive of the presentation will be available on Valeant's corporate website on the Investor Relations page, under the Events and Presentations tab and via this URL: http://ir.valeant.com/events-and-presentations.

First Quarter 2017 Financial Results Conference Call The Company also announced that it plans to release first quarter 2017 financial results on Tuesday, May 9, 2017. Valeant will host a conference call and live webcast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations portion of the corporate website before the start of the conference call.

Conference Call Details

Date

Tuesday, May 9, 2017Time

8:00 a.m. ETWebcast

http://ir.valeant.com/events-and-presentationsParticipant Event Dial-in 

(877) 876-8393 (North America)(443) 961-0178 (International) Participant Passcode

1757022Replay Dial-in

(855) 859-2056 (North America)(404) 537-3406 (International) Replay Passcode

1757022 (replay available until June 9, 2017)

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:
Elif McDonald
514-856-3855
877-281-6642 (toll free)         
elif.mcdonald@valeant.com

Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-2017-annual-meeting-of-shareholders-webcast-and-q1-2017-financial-results-conference-call-300437549.html


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement
2. Valeant Announces Upsizing Of Cash Tender Offer For Its 6.75% Senior Notes Due 2018
3. Valeant Commences Cash Tender Offer For Up To $600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018
4. Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To LOréal
5. Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation
6. Annual Valeant Dermatology to Award $10,000 Scholarships to Students Pursuing Undergraduate and Graduate Degrees
7. Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance
8. Sanpower Group Agrees to Acquire Dendreon From Valeant for $819.9 Million
9. Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118
10. Valeant To Sell Dendreon To Sanpower Group For $819.9 Million In Cash
11. Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To LOreal For $1.3 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... Zealand (PRWEB) , ... September 17, 2019 , ... Called ... in Fast Company’s 2019 Innovation by Design Awards Students category. , It was developed ... the Auckland Bioengineering Institute. , Muss-Bits is comprised of two parts. A “sensor bit” ...
(Date:9/17/2019)... ... 17, 2019 , ... Scientists writing in a 2017 issue ... the progressive destruction of joint cartilage in osteoarthritis are “on the close horizon.” ... limb orthopedic surgeon Alejandro Badia, MD , founder and chief medical officer ...
(Date:9/17/2019)... ... , ... Today, in partnership with Lehman College, Power to ... student and faculty from The City University of New York (CUNY). The panel ... Schuster, MPH; Raffaele M. Bernardo, DO, FACP, AAHIVS and Stuart Chen-Hayes, PhD. In ...
Breaking Medicine Technology:
(Date:9/17/2019)... (PRWEB) , ... September 17, 2019 , ... ... to join the largest accountable care organization (ACO) in the country, the company ... this groundbreaking collaboration to improve care quality and increase cost efficiency. This opportunity ...
(Date:9/17/2019)... ... 17, 2019 , ... Dr. Perry Patel, the dentist ... the American Academy of Facial Esthetics (AAFE) to administer Botox and dermal filler ... conditions such as tooth clenching and grinding, tongue tension, temporomandibular joint disorders, commonly ...
(Date:9/17/2019)... ... September 17, 2019 , ... The Center for Information ... of the third edition of The Gift of Participation. Written by CISCRP Founder, ... families to navigate the clinical research process. The new edition offers a fresh ...
(Date:9/14/2019)... (PRWEB) , ... September 13, ... ... Society (WMIS) showcased several first-in-human studies on the detection and treatment of ... two examples of these ground-breaking studies were noninvasive detection of residual HIV ...
(Date:9/11/2019)... ... September 12, 2019 , ... “Heart Seizures”: a useful ... coronary artery disease as he hopes to prevent anyone from having it and to ... author John Saltwick, a writer who was diagnosed with coronary artery disease. Predicted to ...
Breaking Medicine News(10 mins):